Skip to main content
main-content

Connective tissue diseases

Systemic sclerosis

22-05-2020 | COVID-19 | News

Rheumatic disease patients ‘not over-represented’ in severe COVID-19 cohort

The prevalence of rheumatic diseases is low among patients admitted to the intensive care unit with severe COVID-19, researchers report.

15-05-2020 | Systemic sclerosis | News

Faster progression of SSc expected for patients over 60 years at disease onset

Adults who develop systemic sclerosis at an older age are at greater risk for rapid disease progression than those with a younger age at onset, research suggests.

14-05-2020 | Systemic sclerosis | News

Endocannabinoid system modulator shows potential for diffuse cutaneous SSc

The cannabinoid receptor type 2 agonist lenabasum may improve clinical outcomes and underlying disease pathology in patients with diffuse cutaneous systemic sclerosis, show the results of a first-in-human study.

07-05-2020 | Systemic sclerosis | News

Concise self-management hand program effective for SSc patients

Research indicates that a home-based, self-management program that promotes easy hand exercises and gives direction on moisturizing and warming effectively reduces pain and improves function in the hands of patients with systemic sclerosis.

05-05-2020 | Systemic sclerosis | News

​​​​​​​World Scleroderma Foundation issues preliminary advice on SSc and COVID-19

The World Scleroderma Foundation has released preliminary guidance to address questions on COVID-19 in patients with systemic sclerosis.

03-04-2020 | COVID-19 | News

Mild COVID-19 reported in a patient with SSc–ILD

The authors of a case report discuss the experience of a patient with systemic sclerosis-associated interstitial lung disease who developed a mild form of COVID-19.

04-03-2020 | Systemic sclerosis | News

EMA recommends nintedanib approval for SSc-ILD

Click through to read more

Multidisciplinary approach needed for rheumatology patients with coronary artery disease

An analysis of percutaneous coronary intervention outcomes among people with rheumatic diseases suggests that those with systemic sclerosis have an elevated risk for multiple in-hospital complications, while patients with systemic lupus erythematosus have an increased bleeding risk.

04-02-2020 | Cardiovascular disease | Highlight | News

Multidisciplinary approach needed for rheumatology patients with coronary artery disease

An analysis of percutaneous coronary intervention outcomes among people with rheumatic diseases suggests that those with systemic sclerosis have an elevated risk for multiple in-hospital complications, while patients with systemic lupus erythematosus have an increased bleeding risk.

07-01-2020 | Systemic sclerosis | News

GI bleeding risk significantly raised in people with SSc

People with systemic sclerosis are between two and three times more likely to experience gastrointestinal bleeding than people without the autoimmune condition, research carried out in Taiwan shows.

19-12-2019 | Systemic sclerosis | News

Meta-analysis indicates need for BMD monitoring in SSc patients

Individuals with systemic sclerosis have lower bone mineral density and a higher risk for vertebral fracture than those without the disease, indicate findings from a meta-analysis.

21-11-2019 | Rheumatoid arthritis | News

RA comorbidities signal a need to screen

US researchers have identified a number of chronic conditions associated with rheumatoid arthritis, including some that may predispose to RA development and others that may arise as a result of RA.

01-11-2019 | Infection | News

Burden of opportunistic infections high for patients with polymyositis, dermatomyositis

A 13-year cohort study indicates that systemic rheumatic diseases are associated with an increased incidence of opportunistic infections, and suggests that patients with polymyositis or dermatomyositis have the highest rates.

09-10-2019 | Systemic sclerosis | News

Immunosuppressive therapy reduces progression of mild ILD in patients with SSc

A retrospective study shows that treating mild interstitial lung disease with immunosuppressive drugs preserves lung function in patients with systemic sclerosis.

09-09-2019 | Systemic sclerosis | News

Nintedanib receives FDA approval for SSc-ILD

Click through to read more about this approval

30-07-2019 | Systemic sclerosis | News

Abatacept fails to improve skin disease in SSc trial

Findings from the phase II ASSET trial suggest that patients with diffuse cutaneous systemic sclerosis who are treated with abatacept do not experience significantly greater improvements in skin disease than those given placebo.

18-06-2019 | Systemic sclerosis | EULAR 2019 | News

Nintedanib reduces SSc-ILD progression across various subgroups

Nintedanib slows lung function decline in a variety of patients with systemic sclerosis-associated interstitial lung disease, suggests a subgroup analysis of data from the SENSCIS trial.

14-06-2019 | Systemic sclerosis | EULAR 2019 | News

Safety profile of nintedanib similar in SSc–ILD, IPF

Nintedanib’s safety and tolerability profile is similar in patients with systemic sclerosis-associated interstitial lung disease and those with idiopathic pulmonary fibrosis, according to a comparison of data from the SENSCIS and INPULSIS trials.

14-06-2019 | Systemic sclerosis | EULAR 2019 | News

Pirfenidone disappoints in SSc–ILD trial

Randomized trial findings presented at the EULAR 2019 congress in Madrid, Spain, suggest that pirfenidone does not stabilize or improve lung function in patients with systemic sclerosis-associated interstitial lung disease.

20-05-2019 | Systemic sclerosis | News

Nintedanib slows lung function decline in SSc-associated interstitial lung disease

Findings from the SENSCIS trial indicate that the tyrosine kinase inhibitor nintedanib reduces the annual rate of decline in forced vital capacity among patients with systemic sclerosis-associated interstitial lung disease.

Image Credits